FDA WARNING_LETTER - DRG Instruments GmbH - November 07, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA issued a Warning Letter to DRG Instruments GmbH following a November 4-7, 2024, inspection in Marburg, Germany. The firm manufactures in vitro diagnostic devices, including the Salivary Cortisol ELISA (REF No. SLV-2930) and Salivary Cortisol ELISA RUO (REF No. SLV-2930R).
The Salivary Cortisol ELISA and Salivary Cortisol ELISA RUO are deemed adulterated and misbranded. The firm failed to submit a new premarket notification (510(k)) for significant changes to the Salivary Cortisol ELISA (K051733), including a new monoclonal antibody and a narrower assay measuring range (0.09-30 ng/mL vs. 0.537-80 ng/mL). This change could lead to inaccurate results and misdiagnosis. The Salivary Cortisol ELISA RUO is marketed for research but appears intended for clinical diagnostic use, requiring a 510(k) or PMA.
Quality System Regulation (QSR) violations include inadequate corrective and preventive action procedures (21 CFR 820.100(a)), specifically regarding CAPA No. 2024-14 for the Salivary Testosterone ELISA. Complaint investigation records (21 CFR 820.198(e)) lacked required information like UDI/UPC, complainant
ID · 51bbefc6-dc80-4832-abad-5469bb43fafb
Full citation text and observation details available on the Dashboard.